Phagocyte Function Decreases after High-Dose Treatment with Melphalan and Autologous Stem Cell Transplantation in Patients with Multiple Myeloma.
High-dose melphalan with autologous hematopoietic stem cell transplantation (ASCT) is standard of care for younger newly diagnosed multiple myeloma patients, with the aim of achieving as deep and complete response as possible after various combinations of induction therapy. However, it is frequently associated with infectious complications. This study investigated the effects of high-dose treatmen